Glucagon-like peptide-1 receptor agonists tied to higher thyroid cancer risk in first year of treatment
The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to a ...
GLP-1 drugs like Ozempic may have health benefits, but they come with risks
With with GLP-1 drugs, gastrointestinal issues, such as nausea, vomiting, constipation, and gastroesophageal reflux disease, ...
Medscape8d
The Glucagonostatic and Insulinotropic Effects of Glucagon-like Peptide 1 Contribute Equally to its Glucose-lowering Action
Objective—Glucagon-like peptide 1 (GLP-1) exerts beneficial antidiabetic actions via effects on pancreatic β- and α-cells. Previous studies have focused on the improvements in β-cell function ...
Hosted on MSN8d
It Looks Like Scientists Have Uncovered A Natural Alternative To Ozempic
Scientists may have discovered a way to naturally regulate blood sugar levels and sugar cravings that works similarly to ...
Ulster University2mon
Targeting glucagon-like peptides for the treatment of diabetes and obesity
Glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2) are secreted from the same intestinal cells following meal ingestion. GLP-1 is now widely recognised to reduce blood glucose levels ...
Medscape26d
Early Intervention Central to Treating Muscle Mass Loss in Patients Losing Weight With GLP-1 Meds
With glucagon-like peptide 1 (GLP-1) agonists now close to inducing weight loss at levels only seen before through surgical intervention, obesity specialists say patients on these drugs are ...
standardmedia.co.ke6mon
A full analysis of Retatrutide and Tirzepatide Peptides
Studies suggest that the peptide may activate receptors involved in energy balance, such as the glucagon-like peptide-1 (GLP-1) receptor, glucagon receptor (GCGR), and glucose-dependent ...